Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $25
Benzinga Newsdesk 2 years ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $28 to $25.
Piper Sandler analyst David Westenberg maintains Fulgent Genetics (NASDAQ:FLGT) with a Neutral and lowers the price target from $28 to $25.